Synthesis and Structure−Activity Relationship of a New Series of Potent AT1 Selective Angiotensin II Receptor Antagonists: 5-(Biphenyl-4-ylmethyl)pyrazoles
- 1 February 1997
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (4) , 547-558
- https://doi.org/10.1021/jm9604383
Abstract
The synthesis and pharmacological activity of a new series of 5-(biphenyl-4-ylmethyl)pyrazoles as potent angiotensin II antagonists both in vitro (binding of [3H]AII) and in vivo (iv, inhibition of AII-induced increase in blood pressure, pithed rats; po, furosemide-treated sodium-depleted rats) are reported. The various substituents of the pyrazole ring have been modified taking into account the receptor's requirements derived from related structure-activity relationship studies. A propyl or butyl group at position 1 as well as a carboxylic acid group at position 4 were shown to be essential for high affinity. Different groups at position 3 (H, small alkyl, phenyl, benzyl) provided good binding affinity, but oral activity was highly discriminating: bulky alkyl groups provided the highest potencies. Among the acidic isosteres tested in the biphenyl moiety, the tetrazole group proved to be the best. Compound 14n (3-tert-butyl-1-propyl-5-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-y l] methyl]-1H-pyrazole-4-carboxylic acid, UR-7280) shows high potency both in vitro (IC50 = 3 nM) and in vivo (iv, 61.2 +/- 10% decrease in blood pressure at 0.3 mg/kg; po, 30 mmHg fall in blood pressure at 0.3 mg/kg), in comparison to losartan (IC50 = 59 nM; iv, 62.5 +/- 8.9% decrease in blood pressure at 1 mg/kg; po, 13 mmHg fall in blood pressure at 3 mg/kg). These data, together with the good pharmacokinetic profile of 14n in different species, have led to its selection for clinical evaluation as an antihypertensive agent.Keywords
This publication has 20 references indexed in Scilit:
- Angiotensin-Converting Enzyme and Converting Enzyme InhibitorsPublished by Taylor & Francis ,2018
- Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidasePublished by Elsevier ,2003
- Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive TherapyJournal of Medicinal Chemistry, 1996
- The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological functionTrends in Pharmacological Sciences, 1995
- A medicinal chemistry case study: An account of an angiotensin II antagonist drug discovery programmeTetrahedron, 1994
- Nonpeptide angiotensin II receptor antagonists: the discovery of DMP 581 and DMP 811Bioorganic & Medicinal Chemistry Letters, 1994
- Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensivesJournal of Medicinal Chemistry, 1991
- The Renin-Angiotensin SystemJournal of Cardiovascular Pharmacology, 1990
- Angiotensin Converting Enzyme Inhibitors and CoughJournal of Cardiovascular Pharmacology, 1989
- The renin-angiotensin systemTrends in Pharmacological Sciences, 1987